Secukinumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Secukinumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IL17A
Clinical data
Trade names Cosentyx
AHFS/Drugs.com cosentyx
Pregnancy
category
  • US: B (No risk in non-human studies)
ATC code
Legal status
Legal status
Identifiers
Synonyms AIN457
CAS Number
DrugBank
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6584H10134N1754O2042S44
Molar mass 147.94 kg/mol
 NYesY (what is this?)  (verify)

Secukinumab, trade name Cosentyx, is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A,[1] and is manufactured by Novartis Pharma AG for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It targets member A form of the cytokine family of interleukin 17, severely inhibiting its functioning.[2][3] On January 21, 2015, the United States, the federal Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis.[4][5] On January 15, 2016, the United States, the federal Food and Drug Administration announced that it had approved secukinumab to treat adults with ankylosing spondylitis, and psoriatic arthritis.[6]

Although the drug was originally intended to treat rheumatoid arthritis, phase II clinical trials for this condition yielded disappointing results.[7]

A phase II clinical trial for multiple sclerosis[8] completed in 2014 as it had exhibited efficacy in treating experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Results of this trial have not yet been reported as of April 2015

Standard protocol[edit]

Patients begin treatment with five booster shots of 300 mg subcutaneous each one taken a week apart, followed by regular injections once a month thereafter for 5 months.

References[edit]

  1. ^ http://www.psocialsis.com/medicamentos-det.php?recordID=42
  2. ^ "Statement On A Non-proprietary Name Adopted By The USAN Council: Secukinumab" (PDF). American Medical Association. 
  3. ^ Hueber, W.; Patel, D. D.; Dryja, T.; Wright, A. M.; Koroleva, I.; Bruin, G.; Antoni, C.; Draelos, Z.; Gold, M. H.; Durez, P.; Tak, P. P.; Gomez-Reino, J. J.; Foster, C. S.; Kim, R. Y.; Samson, C. M.; Falk, N. S.; Chu, D. S.; Callanan, D.; Nguyen, Q. D.; Rose, K.; Haider, A.; Di Padova, F.; Rose, K; Haider, A; Di Padova, F (2010). "Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis". Science Translational Medicine. 2 (52): 52ra72. PMID 20926833. doi:10.1126/scitranslmed.3001107. 
  4. ^ "FDA approves new psoriasis drug Cosentyx" (Press release). United States Food and Drug Administration. January 21, 2015. Retrieved January 21, 2015. 
  5. ^ http://www.novartis.com/newsroom/media-releases/en/2015/1888645.shtml
  6. ^ "Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US | Novartis". Novartis. 2016-01-15. Retrieved 2017-02-22. 
  7. ^ http://www.medscape.com/viewarticle/806510_6[full citation needed]
  8. ^ Clinical trial number NCT01874340 for "Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis" at ClinicalTrials.gov